| David Ojala is the Director of AAV Engineering at Sangamo Therapeutics, a genomics medicine company based in the San Francisco Bay Area. He obtained his PhD from the University of California, Berkeley and has over of decade of experience in the field of gene therapy and adeno-associated virus biology. Since joining Sangamo in 2017 he has led the development of a technology platform for AAV capsid engineering. A primary focus of his work is to engineer AAV capsids that can enable transformative genomic medicines for neurological disorders. |
